trial · primary record
Amivantamab
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 308 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT04538664 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:54.403Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04538664
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.